WeTrials
Recruiting

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial

What is this study?

This study is testing if adding a medication called palbociclib to standard cetuximab treatment helps people live longer with a certain type of head and neck cancer. It is for patients whose cancer has grown or spread after trying immunotherapy.

Who can participate?

You may be able to join if you have head and neck cancer that is not caused by HPV, has a specific genetic change called CDKN2A, and has gotten worse after previous immunotherapy treatment. You must not have taken cetuximab or similar targeted drugs for your advanced cancer before.

What will happen?

Participants will be put into one of two groups by chance: one group gets a combination of two targeted cancer medications, while the other group gets cetuximab alone. Your health and cancer will be closely monitored through regular check-ups and scans during the study.

Where and when?

The study is currently active and recruiting participants at locations in Worthington, Minnesota, as well as Kansas City and St. Louis, Missouri.

Key Points
  • 1Tests a combination of two targeted cancer drugs against a single drug treatment.
  • 2Designed for patients whose head and neck cancer has progressed after immunotherapy.
  • 3Currently recruiting patients at multiple medical centers in the United States.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
HPV-unrelated Head and Neck Squamous Cell Carcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.